Therapeutic Workshop
Pre-ASH Primer: Hematology Heavy Hitters Discuss What's on the Horizon?
Thursday, October 30, 2008
9:30am - 10:45am
Twin Peak South
Hear from thought leaders in hematology on what’s likely to be the incremental or the category-defining data at ASH 2008 and in 2009. Where can we expect to be the greatest advances in hematology? Recent strides in the understanding of the pathogenesis of multiple myeloma, for example, have led to new drugs, clinical investigation and treatment strategies and improved survivals. This panel will take a look at current front-line treatment options in multiple myeloma and the new therapeutic options on the horizon for the treatment of leukemias and lymphomas.
Moderator
- Reni Benjamin, PhD, Senior Biotech Analyst, Managing Director at Rodman & Renshaw, LLC
Panelists
Industry:
- Mark L. Reisenauer, Senior Vice President, Chief Commercial Officer, Micromet, Inc.
- Arthur C. Louie, MD FACP, Chief Medical Officer, Celator Pharmaceuticals, Inc.
- Alan Colowick, M.D., Chief Executive Officer, Gloucester Pharmaceuticals, Inc.
Clinician:
- Steven Coutre, MD, Associate Professor of Medicine, Stanford University School of Medicine and Director of the Outpatient Hematology Clinic, Stanford Hospital
Who's Who
Reni Benjamin, PhD Dr. Benjamin is Managing Director and Senior Biotechnology Analyst at Rodman & Renshaw, LLC. His expertise and company coverage consists of small-cap companies in the oncology and stem cell sectors. Dr. Benjamin has previously been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine and has been cited in a variety of sources including the Wall Street Journal, Business Week, Financial Times, Dow Jones Newswire, and Smart Money. He has also made appearances on Bloomberg television/radio and CNBC.
Prior to joining Rodman & Renshaw, Dr. Benjamin was an associate analyst in Needham and Company’s biotechnology equity research department. Prior to that, he earned his doctorate in Biochemistry by discovering and characterizing a novel gene implicated in germ cell development. His expertise includes biochemistry, functional genomics, gene therapy and molecular biology. Dr. Benjamin has presented at various regional and international conferences and published in peer-reviewed journals. Dr. Benjamin received his Ph.D. from the University of Alabama at Birmingham and his Bachelors of Science degree in Biology from Allegheny College.
Alan Colowick, MD A hematologist-oncologist by training, Dr. Colowick brings 10 years of oncology product development experience to Gloucester. Dr. Colowick was President of Geron Oncology from October 2006 until February 2008. Prior positions also include Chief Medical Officer of Threshold Pharmaceuticals Inc., where he was responsible for all aspects of non-clinical and clinical development and manufacturing and various management positions with Amgen, Inc., most recently serving as Vice President of European Medical Affairs, where he was responsible for products in multiple therapeutic areas, including hematology/oncology, nephrology and internal medicine. From 1996 to 1999, Dr. Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Brigham and Women's Hospital/Dana Farber Cancer Institute. Dr. Colowick holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University and a M.P.H from Harvard University.
Arthur C. Louie, MD Dr. Louie is a board certified oncologist with more than 25 years of experience in pharmaceutical research and development. He was a vice president of medical affairs at Human Genome Sciences, Inc. and a vice president of clinical research at Xoma Corporation. He also held leadership roles in clinical development at Pro-Neuron, Inc. Pro-Virus Inc., and Chiron Therapeutics. Dr. Louie was a director of cancer research at Bristol-Myers and consulted for Johnson & Johnson and Genta Incorporated. He was responsible for the successful effort to secure FDA approval for Proleukin IL-2, which is used for treatment of metastatic kidney cancer and for metastatic melanoma. Dr. Louie received a B. A. in Biology with honors from Haverford College, and an M.D. from New York University School of Medicine. He completed oncology fellowships at the National Cancer Institute and at Stanford University.
Mark Reisenauer Mr. Reisenauer has served as Senior Vice President and Chief Commercial Officer since September 2007. He joined Micromet from Abbott, where he was the General Manager of the Oncology Franchise from 2002 to 2006, and most recently Divisional Vice President and General Manager of the Neuroscience franchise. Before joining Abbott, Mr. Reisenauer was the Director of Marketing for Breast Cancer (Portfolio Lead) and the Director of Breast Cancer Products at Pharmacia from 1999 to 2002. From 1997 to 1999, Mr. Reisenauer was the Associate Director of Oncology Global Marketing at Bristol-Myers Squibb and from 1988 to 1999, he held various positions in sales and oncology marketing at Zeneca. Mr. Reisenauer received a BA degree in Political Science from the University of Wisconsin.
Steven Coutre, MD Dr. Coutre is an Associate Professor of Medicine and the Director of the Outpatient Hematology Clinic at the Stanford University School of Medicine and Stanford Hospital. Dr. Coutre's interests involve clinical research in both the hematologic malignancies and thrombotic/hypercoagulable disorders. Dr. Coutre is also involved in the treatment of acute/chornic myeloid leukemia, acute/chronic lymphocytic leukemia, multiple myeloma, prolymphocitic leukemia, hypereosinophilic syndrome, systemic mastocytosis, and heparin-induced thrombocytopenia. Dr. Coutre has experience in the biotechnology industry having previously worked at Gilead Sciences and is a member of the Leukemia committee of the Southwest Oncology Group and the National Comprehensive Cancer Network.